Barbara Klencke

CIK: 0001647647

Transaction Breakdown

Open Market Buys (P)1 (11.1%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)8 (88.9%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

XNCR

Xencor Inc

Director

TCRX

TScan Therapeutics, Inc.

Director

ALXO

ALX ONCOLOGY HOLDINGS INC

Officer

Discretionary Trading P&L

Holdings

Transaction History (9 total)

XNCR
Xencor Inc
Jun 16, 2026
Award(A)
Direct
10.3K shares-
TCRX
TScan Therapeutics, Inc.
May 20, 2026
Award(A)
Stock Option (Right to Buy)
Direct
67K shares-
ALXO
ALX ONCOLOGY HOLDINGS INC
Apr 16, 2026
Award(A)
Stock option (right to buy)
Direct
100K shares-
ALXO
ALX ONCOLOGY HOLDINGS INC
Mar 3, 2026
Award(A)
Stock option (right to buy)
Direct
700K shares-
ALXO
ALX ONCOLOGY HOLDINGS INC
Sep 17, 2025
Award(A)
Stock option (right to buy)
Direct
300K shares-
TCRX
TScan Therapeutics, Inc.
Jun 30, 2025
Award(A)
Stock Option (Right to Buy)
Direct
67K shares-
XNCR
Xencor Inc
Jun 12, 2025
Award(A)
Direct
13.7K shares-
ALXO
ALX ONCOLOGY HOLDINGS INC
Jan 21, 2025
Award(A)
Stock Option (right to buy)
Direct
40.4K shares-
TCRX
TScan Therapeutics, Inc.
Sep 23, 2024
Purchase(P)
Direct
5K shares at avg. $5.29$26K

		Type	Shares	Price		Ownership
Jun 16, 2026	XNCR Xencor Inc	Award(A)	10,302	-	$0	Direct
May 20, 2026	TCRX TScan Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	67,000	-	-	Direct
Apr 16, 2026	ALXO ALX ONCOLOGY HOLDINGS INC	Award(A) Stock option (right to buy)	100,000	-	-	Direct
Mar 3, 2026	ALXO ALX ONCOLOGY HOLDINGS INC	Award(A) Stock option (right to buy)	700,000	-	-	Direct
Sep 17, 2025	ALXO ALX ONCOLOGY HOLDINGS INC	Award(A) Stock option (right to buy)	300,000	-	-	Direct
Jun 30, 2025	TCRX TScan Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	67,000	-	-	Direct
Jun 12, 2025	XNCR Xencor Inc	Award(A)	13,686	-	-	Direct
Jan 21, 2025	ALXO ALX ONCOLOGY HOLDINGS INC	Award(A) Stock Option (right to buy)	40,400	-	-	Direct
Sep 23, 2024	TCRX TScan Therapeutics, Inc.	Purchase(P)	5,000	$5.29	$26,450	Direct

1-9 of 9 transactions

About Klencke Barbara

Klencke Barbara (SEC CIK 0001647647) files insider reports with the SEC as Director of Xencor Inc (XNCR), Director of TScan Therapeutics, Inc. (TCRX) and Chief Medical Officer of ALX ONCOLOGY HOLDINGS INC (ALXO).

Signal8 holds 11 ownership filings by Klencke Barbara (2 Form 3, 9 Form 4), filed between Sep 24, 2024 and Jul 8, 2026. Those filings report 9 transactions, from Sep 23, 2024 to Jun 16, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Klencke Barbara's filings is in PASADENA, CA.

Recent filings by Klencke Barbara

Jun 16, 2026: Grant or award of XNCR shares (Form 4, code A).
May 20, 2026: Grant or award of TCRX derivative securities (Form 4, code A).
Apr 16, 2026: Grant or award of ALXO derivative securities (Form 4, code A).
Mar 3, 2026: Grant or award of ALXO derivative securities (Form 4, code A).
Sep 17, 2025: Grant or award of ALXO derivative securities (Form 4, code A).

Other insiders filing for Xencor Inc (XNCR)

How to read Form 4 transaction codes